Altogether, these data indicate that high expression levels of PSMD1 and PSMD3 mRNA correlate with worse outcomes in multiple different cancers, with the exception of patients with DLBCL, STAD, and THYM. This evidence concerns the gene PSMD3 and diffuse large B-cell lymphoma.